Abstract: A multipurpose solution mixer and a use method thereof are provided. The multipurpose solution mixer includes a main control unit, a solution storage unit and a solution blending unit installed in a case; an operation display unit and a liquid outlet provided on the case; and an atomization humidifying unit connected with the liquid outlet, wherein the main control unit is electrically connected with other units; the operation display unit is a display screen with touch operation functions; the solution storage unit includes sealed bottles and infusion tubes; the solution blending unit includes micropumps infusion tubes and a blending chamber, the blending chamber is connected with the atomization humidifying unit via respective infusion tubes, and the operation display unit sends instructions to the main control unit to control the micropumps to extract solutions from the sealed bottles into the blending chamber, and output a mixed solution via the liquid outlet.

Abstract: A medicated thread manufacturing system and associated method includes first and second slideways, a thread clamping apparatus and a medicine spraying apparatus slidably arranged on the first slideway, and a thread winding apparatus slidably arranged on the second slideway. The clamping apparatus clamps two ends of a to-be-processed medicated thread, straightens the thread and twists the thread in the straightened state into a single-strand rope state. The spraying apparatus sprays a medicine towards a surface layer of the thread in the straightened state. The winding apparatus abuts a center position of the thread in the single-strand rope state, pulls and folds the thread, and rotates the thread such that the thread winds and extends from middle to two ends to be twisted in a double-strand rope state. A control apparatus is in signal connection and/or electrical connection to the clamping apparatus, the spraying apparatus and the winding apparatus.

Abstract: A multipurpose solution mixer and a use method thereof are provided. The multipurpose solution mixer includes a main control unit, a solution storage unit and a solution blending unit installed in a case; an operation display unit and a liquid outlet provided on the case; and an atomization humidifying unit connected with the liquid outlet, wherein the main control unit is electrically connected with other units; the operation display unit is a display screen with touch operation functions; the solution storage unit includes sealed bottles and infusion tubes; the solution blending unit includes micropumps infusion tubes and a blending chamber, the blending chamber is connected with the atomization humidifying unit via respective infusion tubes, and the operation display unit sends instructions to the main control unit to control the micropumps to extract solutions from the sealed bottles into the blending chamber, and output a mixed solution via the liquid outlet.

Abstract: The present invention discloses a PPAR ?/? dual agonist and its application. The PPAR ?/? dual agonist comprises an effective amount of the compounds represented by formula I or/and its pharmaceutically acceptable derivative. Wherein. R1 is selected from alkoxyl or ester group; R2 is selected from hydroxyl or ester group. The PPAR ?/? dual agonist according to the present invention can be used for preparing drugs and functional foods for preventing or/and treating metabolic syndrome, especially glucose or/and lipid disorders, with extensive and bright prospects of application.

Abstract: The present invention provides the use of ATG in the preparation of a reagent for adjusting the activity of PP2A; and the use of ATG in increasing the activity of PP2A in 293T cells. The present invention also provides the use of the arctigenin in the preparation of the medicine for reducing the proteinuria of the diabetic mice. The present invention also provides the use of the arctigenin in the preparation of the reagent for inhibiting the expression of the NOX4 gene. The present invention also provides analogs of arctigenin and application thereof. The present invention provides a novel use of ATG for modulating PP2A activity, and ATG can also significantly reduce proteinuria in diabetic mice. At the same time, arctigenin could significantly inhibit the expression of NOX4 in STZ-eNOS?/? mice glomeruli. The ATG analogs of the present invention are more effective than the native ATG.

Abstract: A compound of formula (I) or a pharmaceutically acceptable salt, hydrate or prodrug thereof for inhibiting Syk activity,

Abstract: The present invention provides the use of ATG in the preparation of a reagent for adjusting the activity of PP2A; and the use of ATG in increasing the activity of PP2A in 293T cells. The present invention also provides the use of the arctigenin in the preparation of the medicine for reducing the proteinuria of the diabetic mice. The present invention also provides the use of the arctigenin in the preparation of the reagent for inhibiting the expression of the NOX4 gene. The present invention also provides analogues of arctigenin and application thereof. The present invention provides a novel use of ATG for modulating PP2A activity, and ATG can also significantly reduce proteinuria in diabetic mice. At the same time, arctigenin could significantly inhibit the expression of NOX4 in STZ-eNOS?/? mice glomeruli. The ATG analogues of the present invention are more effective than the native ATG.

Abstract: The present invention discloses a PPAR ?/? dual agonist and its application. The PPAR ?/? dual agonist comprises an effective amount of the compounds represented by formula I or/and its pharmaceutically acceptable derivative. Wherein. R1 is selected from alkoxyl or ester group; R2 is selected from hydroxyl or ester group. The PPAR ?/? dual agonist according to the present invention can be used for preparing drugs and functional foods for preventing or/and treating metabolic syndrome, especially glucose or/and lipid disorders, with extensive and bright prospects of application.

Abstract: The present invention discloses a novel composition with anti-viral effects comprises extracts from Anemarrhena asphodeloides. Method of preparing said extract is also disclosed.

Abstract: A drug composition for treating chronic liver diseases, consists of: Astragalus Astragalosides and Glycyrrhiza Acid by weight ratio of 3˜6:1. By testing and validating with classic animal model, the results confirmed that the drug composition of the present invention can significantly reduce the collagen content of rat liver, and reduce liver fibrosis and liver injury, wherein the effect is better than the effect of each component alone. The drug composition of the two components or ingredients can improve the anti-hepatic fibrosis, effectively prevent liver fibrosis and promote the development of liver fibrosis reversal, and thus can be used for the treatment and prevention of various chronic hepatitis, liver fibrosis, cirrhosis and other illnesses.

Abstract: An effective fraction from the fruiting bodies of Ganoderma lucidum, extraction method, use and preparation thereof are provided. The effective fraction is prepared from the defatted fruiting bodies of Ganoderma lucidum by extracting with alkali, dialyzing and drying. The effective fraction has effect of significantly lowering blood sugar.